Readoutin 13d
Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair — Topotecan - usual
Phase 3 primary completion: Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms.
- Date
- Dec 2026
- Type
- Readout
- Indication
- SCLC